During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabsto detect the SARS-CoV-2 virus, responsible for the disease. However, this technique hasseveral limitations, including the variable quality of swabs, its invasive nature, andarbitrariness in the choice of the number of cycles. Furthermore, it does not allow forthe detection of viral proteins.To overcome these limitations, researchers developed the eBAM-CoV test, patented for thedetection of viral proteins in the exhaled air of COVID-19 patients. This portable deviceprovides an immediate assessment of the "viral load" with both quantitative andqualitative results, showing promise for early virus detection.The researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactoryconcordance with the reference RT-PCR test in the detection of COVID-19, especially amongsymptomatic patients or closed contacts.
Not Provided
Device: eBAM Cov Testing
Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air
exhaled by the patient compared with the presence/absence of infection based on RT-PCR
testing of nasopharyngeal swabs
Inclusion Criteria:
- Adult male or female patients over 18 years of age (≥)
- Suspected of being infected with COVID-19 (symptomatic or contact case) and
consulting for RT-PCR screening.
Exclusion Criteria:
- Inability to understand the procedures to use the device
- Patient participating in an another interventional study
- Patient in exclusion period determined by another study
- Patient under court protection or guardianship
- Patient/trusted person/legal representative/family member for whom it is impossible
to give informed information.
- Pregnant, parturient or breast-feeding patient
Laboratoire Alphabio, Hôpital Européen Marseille
Marseille, France
CHU de NIMES
Nîmes, France
Valérie COMPAN, PhD
+33664915140
vcompan@brains4d.com
Not Provided